Author  
Place of duty  
Title   국소진행성 비소세포성 폐암에서 5-FU, VinBlastine 및 Cisplatin (FVP)의 수술전 선행 화학요법의 효과 ( The Effect of Neoadjuvant Chemotherapy with 5-Fluorouracil (5-FU), Vinblastine and Cisplatin (FVP) for Stage III Non-Stage III Non-Small Cell Lung Cancer(NSCLC) )
Publicationinfo   1997 Jan; 029(05): 807-816.
Key_word   5-Fluorouracil, Vinblastine, Cisplatin, Neoadjuvant chemotherapy, Non- small cell lung cancer
Full-Text  
Abstract   Purpose: As the prognosis of stage III NSCLC is still poor with or without operation, we conducted a phase II trial of neoadjuvant chemotherapy(CHT) with S-FU, vinblastine, cisplatin prior to surgery to determine the effect on resectability and survival. Materials and Method: Patients(pt) received 5-FU 500mg/m2/12 hours continuous infusion for 36 hours, vinblastine 3mg/m2/day iv bolus day 1 and day 2, and cisplatin 75mg/m2 iv day 1 every 3 weeks. This regimen was given for 2 cycles. When the tumor was responsive(stable disease or better), 1 or 2 more cycles of the CHT were given, followed by operation when totally resectable on chest CT/MRI, then 3 more cycles of the CHT to finish the treatment; when the tumor was neither responsive nor resectable after 3rd or 4th CHT, radiotherapy was started. Result: Twenty nine pt were enrolled and 26 pt have been evaluable so far. Age ranged from 32 to 79(median 59 years); 23 were male, 3 female. Total of 108 cycles were given(mean 4.2). There were 4 partial remissions out of 6 IIIAs(67%) and 10 out of 20 IIIBs(50%), with overall response rate of 53.8%; down staging was noted in 9 patients (34.6%). 9 pt(34.6%) underwent curative resection successfully; 4 out of 6 IIIAs(67%) and 5 out of 20 IIIBs(25.0%); 1 patient refused operation. Median survival was 31.3 months for 9 pt with operation, and that of all patients was 14.2 months. Radiation was given to 9 pt, resulting in 3 partial remissions(PR), 3 stable diseases(SD), 3 progressive diseases(PD). Serious(WHO grade3) toxicities were nausea/emesis in 2.8%, granulocytopenia in 26.9% and thrombocytopenia in 2.8%. Conclusion: This treatment modality seemed to be effective, encouraging further phase III study for better determination of its role.
저 자   원정일(Jung Il Won),천종호(Jong Ho Chun),김형준(Hyung Joon Kim),조문숙(Moon Sook Cho),김동규(Dong Kyu Kim),곽영태(Young Tae Gwak),김정숙(Jung Sook Kim),최수전(Soo Jun Choi),김성록(Sung Rok Kim),